{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/prescribing-information/snris/","result":{"pageContext":{"chapter":{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs","depth":2,"htmlHeader":"<!-- begin field 6b17f681-8665-4107-9625-ab1a00fb3197 --><h2>Serotonin noradrenaline reuptake inhibitors (SNRIs)</h2><!-- end field 6b17f681-8665-4107-9625-ab1a00fb3197 -->","summary":"","htmlStringContent":"<!-- begin item 37873a7a-fecf-4fd4-86cc-ab1a00fb3173 --><!-- end item 37873a7a-fecf-4fd4-86cc-ab1a00fb3173 -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c30e210e-dde6-5d6d-9614-38e5b2bb3943","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 592ee2d8-b140-4bf4-8ce5-ab1a00fc029c --><h3>Contraindications and cautions</h3><!-- end field 592ee2d8-b140-4bf4-8ce5-ab1a00fc029c -->","summary":"","htmlStringContent":"<!-- begin item f14939e0-0e65-46da-ba21-ab1a00fc0276 --><!-- begin field e8775845-923a-4f23-8822-ab1a00fc029c --><ul><li><strong>Do not prescribe serotonin noradrenaline reuptake inhibitors (SNRIs) to people with:</strong><ul><li>Conditions associated with high risk of cardiac arrhythmia.</li><li>Uncontrolled hypertension.</li><li>Hepatic impairment (duloxetine).</li><li>Severe renal impairment – creatinine clearance less than 30 mL/min.1.73m<sup>2 </sup>(duloxetine).</li></ul></li><li><strong>Prescribe SNRIs with caution to people with:</strong><ul><li>A history of bleeding disorders.</li><li>A history of epilepsy.</li><li>A history, or family history of mania or bipolar disorder.</li><li>A recent history of myocardial infarction.</li><li>Cardiac disease.</li><li>Diabetes mellitus — glycaemic control may be affected.</li><li>Hypertension.</li><li>Susceptibility to angle-closure glaucoma, or raised intraocular pressure.</li><li>Susceptibility to hyponatraemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field e8775845-923a-4f23-8822-ab1a00fc029c --><!-- end item f14939e0-0e65-46da-ba21-ab1a00fc0276 -->","subChapters":[]},{"id":"26561926-83f3-5b7f-82bb-8a78b810151b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bc5426a5-1cd3-4282-9cf8-ab1a00fc1049 --><h3>Adverse effects</h3><!-- end field bc5426a5-1cd3-4282-9cf8-ab1a00fc1049 -->","summary":"","htmlStringContent":"<!-- begin item 09c4d8ae-8914-4f46-a997-ab1a00fc1028 --><!-- begin field e0aa2be7-90f8-451c-84b8-ab1a00fc1049 --><ul><li><strong>Cardiac</strong> — palpitation (common); tachycardia, supra ventricular arrhythmia (uncommon). <ul><li><strong>Rarely:</strong> torsade de pointes, QT interval prolongation. Venlafaxine has also been associated with takotsubo or stress cardiomyopathy.</li></ul></li><li><strong>Gastrointestinal</strong> (GI) — dry mouth, nausea (very common); constipation vomiting, diarrhoea, dyspepsia, flatulence, abdominal pain (common); GI haemorrhage, gastroenteritis, dysphagia (uncommon).<ul><li><strong>Rarely</strong>: stomatitis, microscopic colitis.</li></ul></li><li><strong>Nervous system </strong>— headache, somnolence (very common); dizziness, akathisia, lethargy, tremor, paraesthesia (common); nervousness, akathisia, myoclonus, dyskinesia (uncommon).<ul><li><strong>Rarely</strong>: serotonin syndrome, convulsions, psychomotor restlessness, extrapyramidal symptoms.</li></ul></li><li><strong>Psychiatric </strong>— insomnia, anxiety, abnormal dreams, agitation (common); suicidal thoughts, sleep disorder, disorientation (uncommon).<ul><li><strong>Rarely</strong>: suicidal behaviour, mania, hallucinations, aggression, anger.</li></ul></li><li><strong>Skin and subcutaneous tissue </strong>— increased sweating, rash (common); urticaria, dermatitis, photosensitivity (uncommon).<ul><li><strong>Rarely</strong>: Stevens-Johnson syndrome, angioneurotic oedema.</li></ul></li><li>Other adverse effects include:<ul><li>Blood pressure increases, flushing.</li><li>Blurred vision.</li><li>Cholesterol level increases.</li><li>Decreased appetite.</li><li>Sexual dysfunction, erectile dysfunction, ejaculatory problems.</li><li>Fatigue.</li><li>Hepatitis.</li><li>Hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH). </li><li>Increased cholesterol levels.</li><li>Tinnitus.</li><li>Urinary problems.</li><li>Yawning.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2020d</a>]</p><!-- end field e0aa2be7-90f8-451c-84b8-ab1a00fc1049 --><!-- end item 09c4d8ae-8914-4f46-a997-ab1a00fc1028 -->","subChapters":[]},{"id":"2c38dd44-7d5f-57c4-b133-50f811fb255a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2d6b73f1-927f-444e-89b1-ab1a00fc2387 --><h3>Drug interactions</h3><!-- end field 2d6b73f1-927f-444e-89b1-ab1a00fc2387 -->","summary":"","htmlStringContent":"<!-- begin item 862f7a15-7fa2-45ef-887b-ab1a00fc2309 --><!-- begin field 6b9db988-78ca-40d3-a1f1-ab1a00fc2387 --><ul><li><strong>Antifungals</strong> (fluconazole, itraconazole, ketoconazole) — plasma concentration of venlafaxine increased.  With fluconazole the manufacturer advised that concomitant use should only be undertaken when necessary and with caution. For other antifungals the advice is to monitor adverse effects and adjust venlafaxine dose if necessary.</li><li><strong>Aspirin, NSAIDs, anticoagulants and antiplatelets </strong>— increased risk of bleeding if taken concurrently with SNRI.</li><li><strong>Bupropion </strong>— plasma concentration of SNRI increased. Monitor adverse effects and adjust SNRI dose if necessary.</li><li><strong>Carvedilol, metoprolol </strong>— levels may be increased by duloxetine. Monitor blood pressure.</li><li><strong>Ciprofloxacin</strong> — avoid concomitant use because the metabolism of duloxetine is inhibited by ciprofloxacin.</li><li><strong>Clarithromycin, erythromycin</strong> — levels of venlafaxine may be increased. Possible increase risk of QT interval prolongation.</li><li><strong>Coumarins</strong> (for example warfarin) — SNRIs possibly enhance anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR.</li></ul></li><li><strong>Diltiazem, verapamil</strong> — plasma concentration of venlafaxine may be increased. Monitor adverse effects and adjust venlafaxine dose if necessary.</li><li><strong>HIV protease inhibitors</strong> (for example, ritonavir, lopinavir, atazanavir) — levels of venlafaxine may be increased. Monitor for adverse effects and adjust dose of venlafaxine if required.</li><li><strong>Lithium</strong> — concurrent us with SNRI may cause serotonin syndrome. In addition, lithium has been associated with QT prolongation and concurrent use may increase this risk. Monitor for adverse effects.</li><li><strong>Monoamine oxidase inhibitors</strong> (MAOIs) — concurrent use is contraindicated. Fatal reactions may occur (serotonin syndrome).</li><li><strong>SSRIs </strong>(paroxetine, sertraline) — increased risk of serotonin syndrome when given concurrently with an SNRI. Monitor for symptoms of serotonin syndrome (such as fever, tremors, diarrhoea, agitation).<ul><li>Venlafaxine may also increase risk of QT interval prolongation if taken concurrently with an SSRI. Consider ECG monitoring.</li></ul></li><li><strong>Other sedative drugs (alcohol, barbiturates, benzodiazepines)</strong> — SSRIs are sedating and co-administration with other sedating drugs may have a synergistic effect.</li><li><strong>Other drugs, which if taken with SNRI may increase the risk of serotonin syndrome, include:</strong><ul><li>Mirtazapine.</li><li>Opioids — fentanyl, tramadol.</li><li>St John’s wort — avoid concurrent use.</li><li>Triptans — sumatriptan, naratriptan.</li><li>Vortioxetine.</li></ul></li><li><strong>QT interval prolongation </strong>— venlafaxine has been associated with QT prolongation or torsade de pointes but an effect is not established. Possible increased risk of QT interval prolongation if venlafaxine is taken with other drugs known to cause QT interval prolongation. These include:<ul><li><strong>Antiarrhythmics</strong> — amiodarone, dronedarone, quinidine.<ul><li>Dronedarone may also increase venlafaxine levels.</li></ul></li><li><strong>Antipsychotics</strong> — phenothiazine derivatives, pimozide, haloperidol.<ul><li>Venlafaxine may also increase pimozide and haloperidol levels.</li></ul></li><li><strong>Tricyclic antidepressants (TCA)</strong> — clomipramine, imipramine.<ul><li>Venlafaxine may also increase levels of TCAs.</li></ul></li><li><strong>Antibiotics</strong> — sparfloxacin, moxifloxacin.</li><li>Halofantrine, saquinavir, sildenafil, methadone, sotalol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2019f</a>]</p><!-- end field 6b9db988-78ca-40d3-a1f1-ab1a00fc2387 --><!-- end item 862f7a15-7fa2-45ef-887b-ab1a00fc2309 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}